Table 4.
Pharmacokinetic parameters of lopinavir (LPV) in rats (n = 6).
| Formulations | AUC0-t (mg × h/L) | T1/2 (h) | Cmax (mg/L) | Frel (%) a | Frel (%) b |
|---|---|---|---|---|---|
| LPV/RTV NP | 12.64 ± 1.47 | 8.26 ± 3.28 | 1.68 ± 0.13 | 1897.18 ± 449.33 | 158.12 ± 44.66 |
| LPV NP | 7.29 ± 1.30Δ | 6.05 ± 2.02 | 1.22 ± 0.09Δ | 1272.67 ± 324.94 | 102.66 ± 29.65 |
| Kaletra® | 7.11 ± 1.02 | 6.91 ± 1.91 | 1.18 ± 0.19 | / | / |
| LPV raw drug | 0.59 ± 0.08 | 13.79 ± 6.81 | 0.12 ± 0.02 | / | / |
LPV: lopinavir; NP: nanoparticle
Δ
No significant difference in both AUC0-t and Cmax between the LPV NP and the commercial product (Kaletra®) (P > 0.05) while significant difference (P < 0.0001) was observed when comparing all other testing groups.
a
calculated based on AUC0-t by comparing to the LPV raw drug group
b
based on AUC0-t by comparing to Kaletra®